Dose finding study of the combination chemotherapy consisting of irinotecan hydrochloride and pegylated liposomal doxorubicin combination therapy in patients with recurrent ovarian cancer (Phase I trial).

Trial Profile

Dose finding study of the combination chemotherapy consisting of irinotecan hydrochloride and pegylated liposomal doxorubicin combination therapy in patients with recurrent ovarian cancer (Phase I trial).

Discontinued
Phase of Trial: Phase I

Latest Information Update: 12 May 2016

At a glance

  • Drugs Doxorubicin liposomal; Irinotecan
  • Indications Ovarian cancer
  • Focus Adverse reactions
  • Most Recent Events

    • 11 May 2012 Status changed from active, no longer recruiting to discontinued as reported by University Hospital Medical Information Network - Japan.
    • 13 Mar 2012 Status changed from suspended to active, no longer recruiting as reported by University Hospital Medical Information Network - Japan.
    • 23 Dec 2011 Status changed from recruiting to suspended as reported by University Hospital Medical Information Network - Japan.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top